TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02665533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium associated with Codeine
Description: Diclofenac Sodium 50 mg associated with Codeine 50 mg
Study: NCT03600818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form:tablets Route of administration: oral administration
Study: NCT03392181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: To determine whether PET/MR utilizing PYL improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.
Study: NCT02318017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Before neurocognitive testing, Methylphenidate/Placebo will be given

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04046393

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Taiwan Scientific noninvasive blood pressure meter TS-0411
Description: measure autonomic nerve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taiwan Scientific noninvasive blood pressure meter TS-0411
Description: measure autonomic nerve

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Meridian Energy Analysis Device(MEAD)
Description: measure meridian energy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meridian Energy Analysis Device(MEAD)
Description: measure meridian energy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: bacteria culture
Description: use culture swab to culture nasal discharge
Study: NCT03642626

Intervention type: DRUG
Intervention: Fludarabine 30mg/m2 4 doses
Description: 30 mg/m2 IV daily for 4 doses

Intervention type: DRUG
Intervention: Cyclophosphamide 500 mg/m2; 2 doses
Description: 500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine

Intervention type: DRUG
Intervention: Fludarabine 30mg/m2 3 doses
Description: 30 mg/m2 IV daily for 3 doses
Study: NCT04046393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bacteria culture
Description: use culture swab to culture nasal discharge

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nasopharyngoscopic examination
Description: use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
Study: NCT03237975

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine health education
Description: The control group will receive routine health education.
Study: NCT01602159

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Bypass Surgery
Description: Open Bypass Surgery with Autogenous vein or PTFE Graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty and Stenting
Description: Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
Study: NCT03831399

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine
Description: Administration 6 g/day of leucine at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration 6 g/day of lactose at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
Study: NCT02616081

Intervention type: OTHER
Intervention: Clean Intermittent Catheterization
Description: Clean intermittent self catheterization is a standard of care.
Study: NCT03642626

Intervention type: DRUG
Intervention: Fludarabine 30mg/m2 3 doses
Description: 30 mg/m2 IV daily for 3 doses
Study: NCT04046393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasopharyngoscopic examination
Description: use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TCM nasal irrigation
Description: Chinese herbal medicine (licorice) extract solution with buffered salt packet and water in rinse bottle
Study: NCT02115035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vermurafenib
Description: 960 mg of Vermurafenib twice daily orally on a 28 day schedule
Study: NCT03509961

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NGS-MRD
Description: Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NGS-MRD
Description: Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.

Intervention type: DRUG
Group type: OTHER
Intervention: Myeloablative allogeneic HCT with a non-TBI conditioning regimen
Description: Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant
Study: NCT05192421

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Education
Description: Receive wellness education through a weekly email and web portal content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Education
Description: Receive wellness education through a weekly email and web portal content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Education
Description: Receive wellness education through a weekly email and web portal content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Videos
Description: Receive pre-recorded exercise videos through a weekly email and web portal content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Livestream Classes
Description: Receive 3 videoconference group exercise classes per week for 8 weeks.
Study: NCT01012284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: 400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
Study: NCT01291446

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: High flatulogenic diet
Description: During 3-days subjects will consume a diet with high content of fermentable residues
Study: NCT04324450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: The MRI protocol is composed of:~* T1-weighted anatomical sequences~* DTI sequences~* resting functional MRI~* 3D MR spectroscopic imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: The MRI protocol is composed of:~* T1-weighted anatomical sequences~* DTI sequences~* resting functional MRI~* 3D MR spectroscopic imaging
Study: NCT04076267

Intervention type: OTHER
Intervention: Tool assessing symptoms validation
Description: Comparison between 2 tools evaluating the symptoms of patients with advanced cancer: the ESAS12-F and the EORTC QLQ C30 to assess if the ESAS12-F well evaluates the symptoms and if it is easy to complete. The objective is to validate the ESAS12-F, which is easier and shorter than the well validated EORTC QLQ C30
Study: NCT01252615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient only
Description: education, behavioral strategies, psychological interventions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient and partner intervention
Description: education, psychological support, behavioral strategies
Study: NCT03982017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Technology Platform
Description: When the participant navigates to the program, s/he will follow the directions on how to use the program, sign the terms of agreement, put in a password and begin the welcome page. The participant will receive daily prompts to complete brief questionnaires and review specialized content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
Study: NCT04324450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: The MRI protocol is composed of:~* T1-weighted anatomical sequences~* DTI sequences~* resting functional MRI~* 3D MR spectroscopic imaging
Study: NCT00381654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-412
Description: Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
Study: NCT04753047

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03263156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene practices and behavioural intervention
Description: The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem for the next two weeks. The second session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. A follow-up phone call will be made two weeks later to provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
Study: NCT03642626

Intervention type: DRUG
Intervention: Fludarabine 30mg/m2 3 doses
Description: 30 mg/m2 IV daily for 3 doses

Intervention type: DRUG
Intervention: Fludarabine 30mg/m2 3 doses
Description: 30 mg/m2 IV daily for 3 doses

Intervention type: DRUG
Intervention: Cyclophosphamide 500 mg/m2; 3 doses
Description: 500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine

Intervention type: DRUG
Intervention: Cyclophosphamide 500 mg/m2; 3 doses
Description: 500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine

Intervention type: DRUG
Intervention: Cyclophosphamide 500 mg/m2; 3 doses
Description: 500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine

Intervention type: DRUG
Intervention: Cyclophosphamide 500 mg/m2; 3 doses
Description: 500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine

Intervention type: DRUG
Intervention: Fludarabine 25mg/m2 3 days
Description: 25 mg/m2 i.v. daily for 3 days

Intervention type: DRUG
Intervention: Fludarabine 25mg/m2 3 days
Description: 25 mg/m2 i.v. daily for 3 days

Intervention type: DRUG
Intervention: Cyclophosphamide 250 mg/m2; 3 days
Description: 250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine

Intervention type: DRUG
Intervention: Tecartus
Description: TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells

Intervention type: DRUG
Intervention: Tecartus
Description: TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells

Intervention type: DRUG
Intervention: Abecma, Intravenous Suspension
Description: Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.

Intervention type: DRUG
Intervention: Cyclophosphamide 900 mg/m2; 1 day
Description: Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS

Intervention type: DRUG
Intervention: Breyanzi Injectable Product
Description: Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
Study: NCT02138942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Learning Intravenous Resuscitator (LIR) system
Description: The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
Study: NCT03967587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neosense Umbilical Catheter
Description: The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
Study: NCT03370731

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adenotonsillectomy
Description: Resection of adenoidal tissue or hypertrophy tonsils by radiofrequency ablation or other methods.

Intervention type: OTHER
Group type: OTHER
Intervention: Nonsurgical management
Description: Nasal Irrigation or inhaled corticosteroids, etc.
Study: NCT03044041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: IA (intra-articular) tranexamic acid after capsule closure
Study: NCT04324450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive assessment
Description: Battery of neuropsychological tests
Study: NCT03044041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: IA (intra-articular) tranexamic acid after capsule closure
Study: NCT02996760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Factor, Platelet-Derived
Description: 0,5 mL, vaginal use , 3 dose number
Study: NCT03439852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light-to-Moderate Physical Activity / Sedentary Time
Description: 12 weeks of telephone counseling -motivational interviewing designed to increase leisure-time physical activity and decrease amount of sitting each day
Study: NCT02616081

Intervention type: OTHER
Intervention: Indwelling Catheter
Description: Indwelling catheterization is a standard of care.
Study: NCT04324450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive assessment
Description: Battery of neuropsychological tests

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive assessment
Description: Battery of neuropsychological tests
Study: NCT00335049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: progressive addition spectacle lens (bifocal)
Description: Progressive addition lenses (PAL) with a +2.00 D add.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Vision Lenses (SVLs)
Description: Single vision spectacle lenses.
Study: NCT02740231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTA-004 intra-articular injection
Description: Each patient will undergo a single injection of JTA-004 into the knee joint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTA-004 intra-articular injection
Description: Each patient will undergo a single injection of JTA-004 into the knee joint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTA-004 intra-articular injection
Description: Each patient will undergo a single injection of JTA-004 into the knee joint

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference product intra-articular injection
Description: Each patient will undergo a single injection of Reference product into the knee joint
Study: NCT01204359

Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Iodine 131
Description: iodine 131，185、370、555mBq，6 months
Study: NCT01277614

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic lifestyle
Description: This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle
Description: This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
Study: NCT03220100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepped Palliative Care
Description: Palliative care clinicians will develop a therapeutic relationship with participants and address their symptoms, coping, prognostic awareness and illness understanding, treatment decision-making, and end of life care needs and preferences.
Study: NCT00879749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9 micrograms Nexvax2
Description: 9 micrograms, weekly intra-dermal injection, 3 week duration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 micrograms Nexvax2
Description: 30 micrograms, weekly intra-dermal injection, 3 week duration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90 micrograms Nexvax2
Description: 90 micrograms, weekly intra-dermal injection, 3 week duration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 micrograms Nexvax2
Description: 60 micrograms, weekly intra-dermal injection, 3 week duration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Up to 900 micrograms Nexvax2
Description: Up to 900 micrograms, weekly intra-dermal injection, 3 week duration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 microlitres 0.9% sterile sodium chloride for injection
Study: NCT00290810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT00739739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0299685 at 15mg BID
Description: 5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0299685 at 30mg BID
Description: 10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for PD 0299685
Description: Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
Study: NCT03921580

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Canned Tuna
Description: 210 g/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched Canned Tuna Variety 1
Description: 210 g/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched Canned Tuna Variety 2
Description: 210 g/day
Study: NCT02584465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen: 40 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Stivarga; 120mg/day
Study: NCT03830086

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane

Intervention type: DRUG
Group type: OTHER
Intervention: Sufentanil
Description: Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane

Intervention type: DRUG
Group type: OTHER
Intervention: Sufentanil
Description: Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane

Intervention type: DRUG
Group type: OTHER
Intervention: Rocuronium
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
Study: NCT01330641

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection of Subacromial Bursa
Description: Injection of steroid and anesthetic to relieve pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection of Subacromial Bursa
Description: Injection of steroid and anesthetic to relieve pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection of Subacromial Bursa
Description: Injection of steroid and anesthetic to relieve pain
Study: NCT03903744

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioneuroablation
Description: The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.
Study: NCT03830086

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
Study: NCT01847820

Intervention type: DEVICE
Intervention: AmniSure ROM test
Description: Comparison of AmniSure ROM test to clinical diagnosis of ROM.
Study: NCT01835379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oasis
Description: Oasis Ultra will be applied once per week for up to 12 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard